#88: The Machine: MIV Therapeutics Appoints Mark Landy to Additional Post of Chief Executive Officer
(OTCBB: MIVT)
(FRANKFURT: MIV), a leading developer of next-generation coatings... |
January 25, 2008
06:19:49 AM |
#87: NewsBot: MIV Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
MIV Therapeutics, Inc. (OTCBB: MIVT)
(FRANKFURT: MIV), a leading... |
November 26, 2007
02:24:54 PM |
#86: FastFun: MIV Therapeutics to Sell Israeli Subsidiary SagaX
MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIV), a leading developer... |
November 23, 2007
06:29:07 AM |
#85: NewsBot: MIV Therapeutics Announces Live VESTASYNC Follow-Up Case Performed At TCT Conference
ATLANTA, Oct. 23, 2007 (PRIME NEWSWIRE) -- MIV Therapeutics, Inc. (OTCBB:MIVT)... |
October 29, 2007
08:32:42 AM |
#84: NewsBot: Results of First-In-Man Study With MIVT Low Dose Polymer-Free Drug-Eluting Stent to Be Presented at TCT Conference
Company Presence at TCT to Include One Oral Presentation and Two Posters
... |
October 20, 2007
09:50:52 AM |
#83: NewsBot: MIVT News MIV Therapeutics Executes Private Financings for $4 Million to Support Acquisitions, Development and Distribution of Next Generation Stents
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a... |
January 8, 2007
12:30:00 AM |
#82: NewsBot: MIVT News Investrend Affiliate SISM Research 'Morning Note' Reiterates MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation, Citing Plans To Introduce New Products In Key Global Markets Next Quarter
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a... |
December 18, 2006
07:03:00 AM |
#81: NewsBot: MIVT News MIV Therapeutics Announces Market Launch of the GenX CrCo Stent and Seven Associated Interventional Cardiology Products by Biosync Scientific
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a... |
December 14, 2006
12:30:00 AM |
#80: NewsBot: MIVT News MIV Therapeutics Executes Milestone Agreement to Acquire Biosync Scientific, a Leading Indian Interventional Cardiology Company
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB: MIVT) (FWB: MIV), a... |
December 11, 2006
12:30:00 AM |
#79: NewsBot: MIVT News MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation Reiterated In Research Note By Investrend Affiliate SISM Research, Indicating Greater Market Potential And Citing Recent Superior Performance of Stent Coating Technologies In Recent Tests
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a... |
December 8, 2006
05:30:00 AM |
#78: NewsBot: MIVT News MIV Therapeutics Announces Company's Biocompatible Stents Matches or Outperforms World's Leading Drug-Eluting Stent in Key Categories
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a... |
November 29, 2006
01:00:00 PM |
#77: NewsBot: MIVT News MIV Therapeutics Releases New Corporate Video Presentation on Company's Programs to Develop Advanced HAp-Based Drug-Eluting Cardiovascular Stents
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a... |
November 6, 2006
01:01:00 PM |
#76: NewsBot: MIVT News MIV Therapeutics Announces Timeline for First Human Implantation of HAp NanoFilm Coated Stent
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT)
(FWB:MIV), a... |
October 27, 2006
01:01:00 PM |
#75: NewsBot: MIVT News MIV Therapeutics to Detail Research Results Showing Excellent Performance of Breakthrough Stent Coatings at TCT Conference
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT)
(FWB:MIV),... |
October 23, 2006
07:11:00 AM |
#74: NewsBot: MIVT News MIV Therapeutics Appoints Montreal Heart Institute Interventional Cardiologist Dr. Raoul Bonan to Guide Clinical Programs; World Renowned Specialist Brings Extensive Clinical Trial Expertise
ATLANTA--(BUSINESS WIRE)--Sept. 21, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV),... |
September 21, 2006
03:30:00 AM |
| 
| 
| 
| 
| 
| 
